Share on StockTwits

AcelRx Pharmaceuticals (NASDAQ:ACRX)‘s stock had its “outperform” rating reiterated by investment analysts at Cowen and Company in a note issued to investors on Tuesday. They currently have a $14.00 price target on the stock, down from their previous price target of $15.00. Cowen and Company’s price target would suggest a potential upside of 119.09% from the stock’s previous close.

AcelRx Pharmaceuticals (NASDAQ:ACRX) traded up 3.05% on Tuesday, hitting $6.585. 1,170,070 shares of the company’s stock traded hands. AcelRx Pharmaceuticals has a 52-week low of $6.04 and a 52-week high of $13.64. The stock’s 50-day moving average is $10.10 and its 200-day moving average is $10.7. The company’s market cap is $285.2 million.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last announced its earnings results on Thursday, May 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. On average, analysts predict that AcelRx Pharmaceuticals will post $-1.01 earnings per share for the current fiscal year.

ACRX has been the subject of a number of other recent research reports. Analysts at Piper Jaffray downgraded shares of AcelRx Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Tuesday. They now have a $8.00 price target on the stock, down previously from $14.00. Separately, analysts at JMP Securities cut their price target on shares of AcelRx Pharmaceuticals from $14.00 to $12.00 in a research note on Monday. They now have an “outperform” rating on the stock. Finally, analysts at RBC Capital cut their price target on shares of AcelRx Pharmaceuticals from $15.00 to $12.00 in a research note on Monday. They now have an “outperform” rating on the stock. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. AcelRx Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $13.17.

AcelRx Pharmaceuticals, Inc is a United States-based Pharmaceutical Company, which develops and commercializes therapies for the treatment of pain.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.